Literature DB >> 25638561

Inhibition of mutant IDH1 in acute myeloid leukaemia.

Farhat Yaqub.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25638561     DOI: 10.1016/S1470-2045(14)71140-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  6 in total

Review 1.  The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice.

Authors:  Frank C Kuo; Brenton G Mar; R Coleman Lindsley; Neal I Lindeman
Journal:  Blood       Date:  2017-06-09       Impact factor: 22.113

2.  Isocitrate dehydrogenase mutations are associated with altered IL-1β responses in acute myeloid leukemia.

Authors:  Kathryn I Sunthankar; Matthew T Jenkins; Candace H Cote; Sweta B Patel; Robert S Welner; P Brent Ferrell
Journal:  Leukemia       Date:  2021-12-02       Impact factor: 12.883

3.  Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.

Authors:  Courtney D DiNardo; Farhad Ravandi; Sam Agresta; Marina Konopleva; Koichi Takahashi; Tapan Kadia; Mark Routbort; Keyur P Patel; Sherry Pierce; Guillermo Garcia-Manero; Jorge Cortes; Hagop Kantarjian
Journal:  Am J Hematol       Date:  2015-08       Impact factor: 13.265

Review 4.  Evolving Molecular Genetics of Glioblastoma.

Authors:  Qiu-Ju Li; Jin-Quan Cai; Cheng-Yin Liu
Journal:  Chin Med J (Engl)       Date:  2016-02-20       Impact factor: 2.628

Review 5.  Isocitrate dehydrogenase mutations in myeloid malignancies.

Authors:  B C Medeiros; A T Fathi; C D DiNardo; D A Pollyea; S M Chan; R Swords
Journal:  Leukemia       Date:  2016-10-10       Impact factor: 11.528

6.  The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo.

Authors:  Johnny Suijker; Hans J Baelde; Helene Roelofs; Anne-Marie Cleton-Jansen; Judith V M G Bovée
Journal:  Oncotarget       Date:  2015-06-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.